These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30810966)

  • 1. A Syngeneic ErbB2 Mammary Cancer Model for Preclinical Immunotherapy Trials.
    Pénzváltó Z; Chen JQ; Tepper CG; Davis RR; Silvestrini MT; Umeh-Garcia M; Sweeney C; Borowsky AD
    J Mammary Gland Biol Neoplasia; 2019 Jun; 24(2):149-162. PubMed ID: 30810966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Syngeneic mouse mammary carcinoma cell lines: two closely related cell lines with divergent metastatic behavior.
    Borowsky AD; Namba R; Young LJ; Hunter KW; Hodgson JG; Tepper CG; McGoldrick ET; Muller WJ; Cardiff RD; Gregg JP
    Clin Exp Metastasis; 2005; 22(1):47-59. PubMed ID: 16132578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion.
    Chaganty BKR; Qiu S; Gest A; Lu Y; Ivan C; Calin GA; Weiner LM; Fan Z
    Cancer Lett; 2018 Aug; 430():47-56. PubMed ID: 29746929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling.
    Passariello M; D'Alise AM; Esposito A; Vetrei C; Froechlich G; Scarselli E; Nicosia A; De Lorenzo C
    Sci Rep; 2019 Sep; 9(1):13125. PubMed ID: 31511565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer.
    Wang Q; Guldner IH; Golomb SM; Sun L; Harris JA; Lu X; Zhang S
    Nat Commun; 2019 Aug; 10(1):3817. PubMed ID: 31444334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice.
    Balasis ME; Forinash KD; Chen YA; Fulp WJ; Coppola D; Hamilton AD; Cheng JQ; Sebti SM
    Clin Cancer Res; 2011 May; 17(9):2852-62. PubMed ID: 21536547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy.
    Hou Y; Nitta H; Wei L; Banks PM; Parwani AV; Li Z
    Clin Breast Cancer; 2018 Apr; 18(2):e237-e244. PubMed ID: 29198959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Membrane Mucin Muc4 promotes blood cell association with tumor cells and mediates efficient metastasis in a mouse model of breast cancer.
    Rowson-Hodel AR; Wald JH; Hatakeyama J; O'Neal WK; Stonebraker JR; VanderVorst K; Saldana MJ; Borowsky AD; Sweeney C; Carraway KL
    Oncogene; 2018 Jan; 37(2):197-207. PubMed ID: 28892049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer.
    Lal JC; Townsend MG; Mehta AK; Oliwa M; Miller E; Sotayo A; Cheney E; Mittendorf EA; Letai A; Guerriero JL
    Breast Cancer Res; 2021 Aug; 23(1):83. PubMed ID: 34353349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors.
    Tobias J; Battin C; De Sousa Linhares A; Lebens M; Baier K; Ambroz K; Drinić M; Högler S; Inic-Kanada A; Garner-Spitzer E; Preusser M; Kenner L; Kundi M; Zielinski CC; Steinberger P; Wiedermann U
    Front Immunol; 2020; 11():895. PubMed ID: 32528470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
    Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS
    Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice.
    Ma Z; Parris AB; Xiao Z; Howard EW; Kosanke SD; Feng X; Yang X
    J Exp Clin Cancer Res; 2017 Jan; 36(1):6. PubMed ID: 28061785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown.
    Zhang Y; Xie X; Yeganeh PN; Lee DJ; Valle-Garcia D; Meza-Sosa KF; Junqueira C; Su J; Luo HR; Hide W; Lieberman J
    Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33627408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade.
    Wakita D; Iwai T; Harada S; Suzuki M; Yamamoto K; Sugimoto M
    Anticancer Res; 2019 Apr; 39(4):1749-1760. PubMed ID: 30952714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
    Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
    Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
    [No Abstract]   [Full Text] [Related]  

  • 17. Development and Preclinical Application of an Immunocompetent Transplant Model of Basal Breast Cancer with Lung, Liver and Brain Metastases.
    Aprelikova O; Tomlinson CC; Hoenerhoff M; Hixon JA; Durum SK; Qiu TH; He S; Burkett S; Liu ZY; Swanson SM; Green JE
    PLoS One; 2016; 11(5):e0155262. PubMed ID: 27171183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity.
    Markosyan N; Chen EP; Evans RA; Ndong V; Vonderheide RH; Smyth EM
    Breast Cancer Res; 2013; 15(5):R75. PubMed ID: 24004819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling.
    Liu B; Ordonez-Ercan D; Fan Z; Huang X; Edgerton SM; Yang X; Thor AD
    Mol Cancer Res; 2009 Nov; 7(11):1882-92. PubMed ID: 19861407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Generation and comparison of two genetically engineered mouse models of ErbB2/Neu positive-PTEN deficient breast cancer].
    Wang QF; Ding H; Liu BR; Zhang K
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 43(4):427-33. PubMed ID: 25187457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.